Overview

Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer

Status:
Not yet recruiting
Trial end date:
2027-07-30
Target enrollment:
Participant gender:
Summary
To evaluate the tolerability, safety, pharmacokinetic characteristics and immunogenicity of Almonertinib combined with SHR-1701 in relapsed or advanced NSCLC To evaluate the efficacy of Almonertinib combined with SHR-1701 in the first-line treatment of relapsed or advanced NSCLC
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Suzhou Suncadia Biopharmaceuticals Co., Ltd.